Ratings Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Market Closed - Australian S.E. Other stock markets 02:10:53 2024-05-16 am EDT			5-day change	1st Jan Change
0.61 ^AUD	0.00%		-8.27%	+14.02%

May. 15	Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial	MT
May. 10	Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
RECCE PHARMACEUTICALS LTD	+14.02%	83.16M	-
ELI LILLY AND COMPANY	+32.36%	709B	C+
NOVO NORDISK A/S	+30.77%	595B	B
JOHNSON & JOHNSON	-1.60%	367B	C+
MERCK & CO., INC.	+20.07%	334B	B-
ABBVIE INC.	+6.04%	289B	C+
ASTRAZENECA PLC	+14.77%	239B	B+
NOVARTIS AG	+9.13%	211B	B-
ROCHE HOLDING AG	-3.97%	203B	A+
AMGEN INC.	+9.27%	171B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes